| Document |
Document Title |
|
WO/2024/017257A1 |
The present application relates to an aromatic substituent-containing heteroaryl- or phenyl-imidazole compound, and a stereoisomer, hydrate, solvate, pharmaceutically-acceptable salt or prodrug thereof. The present application also relat...
|
|
WO/2024/016783A1 |
Disclosed in the present invention is a method for preparing a 6-substituted chirally pure difluoropiperidine quinazoline derivative, specifically, a 6-substituted chirally pure difluoropiperidine quinazoline derivative as represented by...
|
|
WO/2024/017762A1 |
The present invention related to compounds of Formula (I): or an agronomically acceptable salt thereof, wherein R1, R2, R3, R4 and R5 are as described herein. The invention further relates to compositions comprising said compounds, to me...
|
|
WO/2024/012570A1 |
A compound as represented by general formula (I), or a stereoisomer, a deuterated form, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a co-crystal thereof; and intermediates thereof, and the use thereof in AR-...
|
|
WO/2024/015346A1 |
Described herein are compounds and conjugates of Formulae I and II and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as cereblon-binding agents and bifunctional degraders for ce...
|
|
WO/2024/015565A1 |
The present disclosure provides, in certain embodiments, crystalline forms of and a process for preparing a compound having the structure: which is contemplated as a molecular glue that binds cereblon and mediate the degradation of a pro...
|
|
WO/2024/015229A1 |
Provided herein are compounds, conjugate products thereof, methods, and pharmaceutical compositions for use in treatment and diagnosis.
|
|
WO/2024/015503A1 |
Provided are compounds of the Formula (I) or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.
|
|
WO/2024/013567A1 |
The disclosure is directed to compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. The disclosure is also directed to pharmaceutical compositions containing compounds of Formula (I) and pharmaceutically ac...
|
|
WO/2024/013018A1 |
The present invention relates to compounds of Formula (I), or an agronomically acceptable salt of said compounds wherein A, Q, R1, R2, R3 and m are as defined herein. The invention further relates to herbicidal compositions which compris...
|
|
WO/2024/012496A1 |
Provided in the present invention is a cannabinoid receptor compound as represented by formula I. The compound has good binding capacity and inverse agonistic activity on a human CB1 receptor, and almost does not display the inverse agon...
|
|
WO/2024/015497A1 |
This disclosure relates to compounds of Formula (I) or pharmaceutically acceptable salts thereof, in which all of the variables in Formula (I) are as defined in the application. The compounds of this disclosure are capable of inhibiting ...
|
|
WO/2024/015618A2 |
The present disclosure relates to substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione/2-(6-dioxopiper
idin-3-yl) isoindoline-1,3-dione analogs that useful as modulators of cereblon (CRBN) activity, methods of making same, pharmaceut...
|
|
WO/2024/012021A1 |
The present invention relates to the technical field of proteolysis-targeting chimerias (PROTACs). Disclosed are a PROTAC molecule and a preparation method therefor and a use thereof. A target protein ligand in the PROTAC molecule of the...
|
|
WO/2024/015759A1 |
The general field of the present disclosure are novel approaches to the treatment of Alzheimer's and other neurodegenerative disorders using novel therapeutics comprising SHIP1 phosphatase inhibitors. Specifically, the disclosure provide...
|
|
WO/2024/012461A1 |
A class of compounds having methyltransferase inhibitory activity. A compound has a structure as represented by formula I, and can be used for treating and preventing diseases related to a PRC2 complex or a constituent monomer thereof.
|
|
WO/2024/011450A1 |
Described herein are synthetic methods to prepare N- [4- [4- (4-morpholinyl) -7H-pyrrolo [2, 3-d] pyrimidin-6-yl] phenyl] -4- [ [3- [ (1-oxo-2-propen-1-yl) amino] -1-piperidinyl] methyl] -2-pyridinecarboxamide, an irreversible covalent i...
|
|
WO/2024/013209A1 |
Disclosed herein are PCSK9 inhibitors. Also disclosed herein are methods of using PCSK9 inhibitors to treat certain diseases and disorders.
|
|
WO/2024/014637A1 |
The present disclosure relates to a method for preparing a perampanel derivative comprising a continuous flow process.
|
|
WO/2023/280638A9 |
The application relates to vinyl thianthrenium compounds Vinyl- TT+X- of the Formula (I), a process for preparing the same and the use thereof for vinylating organic compounds.
|
|
WO/2024/015918A2 |
The present disclosure provides novel chemotypes, pharmaceutical compositions thereof, and method of use thereof for treating parasitic infection, including infection caused by parasitic flatworms. The present compounds may be useful as ...
|
|
WO/2024/014885A1 |
The present invention provides a novel compound represented by chemical formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof. With an excellent inhibitory activity against PIKfyve, the novel compound of the...
|
|
WO/2024/015861A1 |
Provided herein are methods of preparation of compound 101. Also provided are intermediate compounds useful in the preparation of compound 101, and methods of preparation of those intermediate compounds.
|
|
WO/2024/015637A1 |
The application relates to relates to glutathione peroxidase 4 (GPX4) inhibitors of the general Formulae I and II which induce ferroptosis in a cell and are useful for the treatment of cancer.
|
|
WO/2024/011116A2 |
The disclosure relates to compounds that act as irreversible inhibitors interleukin 1 (IL-1 ) receptor-associated kinases (IRAKs); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediate...
|
|
WO/2024/007985A1 |
The present application provides a compound represented by formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same. The compound, the stereoisomer of the compoun...
|
|
WO/2024/009215A1 |
Provided herein are novel compounds, e.g., those of Formula (I), as GCN2 inhibitors. Also provided are pharmaceutical compositions including one or more of the novel compounds, and pharmaceutical uses thereof. Compounds provided herein c...
|
|
WO/2024/008113A1 |
The present invention relates to a formamide-substituted heterotricyclic derivative represented by formula (I), a method for preparing same, and use thereof. The present invention further relates to a pharmaceutical composition comprisin...
|
|
WO/2024/008179A1 |
Provided herein are compounds having the following structure: wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of KRAS G12D.
|
|
WO/2024/008138A1 |
A pharmaceutical combination of a 1,3,5-triazine derivative. Specifically, the present invention relates to a pharmaceutical combination of a compound of formula I, a tautomer thereof or a pharmaceutically acceptable salt thereof, and az...
|
|
WO/2024/010015A1 |
Compounds represented by general formula (1), the compounds having strong inhibitory action against mPGES-1 and being useful as active ingredients for pharmaceuticals for the treatment of inflammation and the like.
|
|
WO/2024/008941A1 |
Compounds of Formula (I): wherein R1, R2, R3, R4 and are as defined in the description. Medicaments.
|
|
WO/2024/008121A1 |
Disclosed are a series of difluoro-substituted azabicyclo compounds and uses thereof, and specifically disclosed are a compound represented by formula (V) and a pharmaceutically acceptable salt thereof.
|
|
WO/2024/008833A1 |
A prodrug kit for multifactorial dynamic chemotherapy comprises N different small-molecule- drug-conjugates selected from the group comprising Si = Fci―Li―Cti with i = 1, 2, 3, …., 360 wherein 2 ≤ N ≤ 360, Fci is a moiety that ...
|
|
WO/2023/169480A9 |
Provided are a deuterated compound represented by formula IA or a pharmaceutically acceptable salt thereof, a preparation method therefor and a use thereof. Some deuterated compounds have a half-life period of up to 2-4 times that of BVD...
|
|
WO/2024/008083A1 |
A compound as a CDK7 kinase inhibitor and the use thereof. The compound has a structure as shown in formula I, can be used as a cyclin-dependent kinase 7 (CDK7) inhibitor, and is used for treating or preventing proliferative diseases (su...
|
|
WO/2024/011075A2 |
A light delivery device for delivering light therapy includes a light source configured to emit light, one or more first piercing members extending from a distal surface of the light delivery device, the one or more first piercing member...
|
|
WO/2024/008048A1 |
Disclosed is a novel substituted pyrimidoheterocyclic compound, which can be used as an EGFR mutation target inhibitor. Specifically disclosed are a compound represented by the structure in formula (I) or pharmaceutically acceptable salt...
|
|
WO/2024/009144A1 |
Provided herein is a method for the manufacture of a compound of obicetrapib and salts thereof, such as calcium salts thereof. Also provided herein is amorphous obicetrapib hemicalcium. New intermediates for use in the synthesis of obice...
|
|
WO/2024/010818A2 |
This disclosure is directed to proteolysis targeting chimera (PROTAC) of selective androgen receptor degrader (SARD) compounds which are useful in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, ...
|
|
WO/2024/010585A1 |
Provided herein are compounds of formula (I) or (I-A), which act as non-covalent inhibitors of SARS-CoV2 main protease (Mpro). The compounds of formula (I) or (I-A) are useful in treating, ameliorating, and/or preventing COVID-19 infecti...
|
|
WO/2024/010817A2 |
This disclosure is directed to selective androgen receptor degrader (SARD) compounds, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple ne...
|
|
WO/2024/009308A1 |
The present invention involves novel TRPV2 blockers, pharmaceutical compositions comprising the same and uses thereof for the treatment of inflammatory response in inflammation mediated disease processes.
|
|
WO/2024/002206A1 |
Provided is a bifunctional compound, or a pharmaceutically acceptable salt, hydrate, solvate, metabolite or prodrug thereof, wherein the bifunctional compound is represented by Formula (I) : ABM-L-CLM (I); wherein: ABM is an androgen rec...
|
|
WO/2024/006559A1 |
Compounds are provided for inhibiting NLRP3 inflammasome generally, or for treating a NLRP3 inflammasome dependent condition more specifically, by contacting the NLRP3 inflammasome or administering to a subject in need thereof, respectiv...
|
|
WO/2024/000615A1 |
A compound capable of being used as a protein tyrosine kinase inhibitor, which can inhibit AXL, KDR and/or CSF-1R kinase. The compound can also be used for preparing a drug for treating a tumor and a related disease caused by AXL, KDR an...
|
|
WO/2024/002328A1 |
Provided are a nitrogen-containing compound and use thereof. Specifically, provided is a nitrogen-containing compound represented by formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, a met...
|
|
WO/2024/002377A1 |
Provided is a class of compounds with methyltransferase inhibitory activity. Specifically, provided is a class of compounds with PRMT5 inhibitory activity. The compounds can be used for preparing a pharmaceutical composition for treating...
|
|
WO/2024/003749A1 |
Provided are novel compounds represented by Formula (I) which degrade CK1α (casein kinase 1 alpha), and methods of degrading CK1α, or preventing or treating blood cancer by administering the compounds to a subject in need thereof.
|
|
WO/2024/006776A1 |
The application relates to bifunctional compounds which act as degraders of the estrogen receptor alpha (ERα) and are useful for treating disorders associated with ERα-mediated transcription regulation such as endometriosis and cancer....
|
